

Cardiac Involvement in Patients with Systemic Lupus Erythematosus

Mahdi Saleh Alzaidi*; F.I.C.M.S (med) F.I.C.M.S (cardiol), Adil S. Abdul Ghafour**; FRCP(C) ,FACC

Cardiologist, Ibn Al-Bitar Hospital, Baghdad, Iraq

***Professor of medicine, Baghdad College of Medicine, Baghdad, Iraq*

Abstract

Background: The aim this study was to analyze the patterns of involvement of the heart in our patients with SLE by means of clinical evaluation, electrocardiography, and echocardiography.

Methods: Forty six consecutive patients (40 females and 6 males) with systemic lupus erythematosus (SLE) were studied for cardiac manifestations of the disease. Clinical history, physical examination, electrocardiography, chest X ray ,echocardiography study and standard laboratory tests were performed .Thirty three patients (72%) have evidence of cardiac involvement .

Results: Thirty one patients (67%) were found to have abnormal echocardiography findings. Reduction in shortening fraction which reflects reduction in left ventricular function was the commonest abnormality. It was present in 15 patients (33%). Endocardial involvement in form of valvular dysfunction with or with out thickening was found in 10 patients (22%).

Conclusion: The heart is a common target for systemic lupus erythematosus. Therefore, echocardiography should be performed periodically in SLE patients.

Key words: lupus erythematosus, heart, echocardiography.

Introduction

Systemic lupus erythematosus (SLE) is a multisystem connective tissue disease characterized by the presence of numerous autoantibodies ,circulating immune complexes, and wide spread of immunologically determined tissue damage.⁽¹⁾ The earliest description of SLE were as cutaneous disease only.² Osler in 1895 and 1904 noted endocarditis and pericarditis as part of recurrent manifestation of an exudative erythema group of diseases. Libman and Sacks in 1924 brought attention to the cardiac manifestation of lupus with their description of four cases of nonbacterial "verrucous" endocarditis.⁽²⁾ Gross in 1932 and 1940 pointed out the significance of pericardial and

myocardial lesions associated with this syndrome.⁽²⁾

Cardiac manifestations are common in lupus patients and include pericarditis , myocarditis ,endocarditis and coronary artery disease.⁽³⁾ The most characteristic finding is endocardial involvement as described by Libman and Sacks as bland verrucous endocarditis affecting predominantly atriocentric valves of the left side.⁽³⁾ They occur in the forward direction of blood flow and in contrast to rheumatic heart diseases were situated away from the line of closure to involve the most distal part of chordae tendineae, papillary muscle and mural endocardium.⁽⁴⁾

The type of lesion is regurgitant lesions rather than stenotic and affect mitral valve then the aortic valve in

frequency of involvement.⁽⁵⁾ They are present in 43% of SLE patients at autopsy 2, however the prevalence in living patients has not been established, since cardiac involvement is usually clinically silent.

The aim this study was to analyze the patterns of involvement of the heart in our patients with SLE by means of clinical evaluation, electrocardiography, and echocardiography.

Methods

Forty six consecutive patients with SLE were included in this study. They attend the medical city teaching hospital during the period from June 1993 to June 1994; all patients met the 1982 revised diagnostic criteria of the American Rheumatism association for the classification of SLE.⁽⁶⁾

Patients who did not meet four of the revised criteria, those who had history of rheumatic heart disease and those who had unsatisfactory echocardiography were excluded from the study. A thorough clinical history was obtained, and detailed clinical examination of cardiovascular system

was performed for all patients. Twelve lead electrocardiography (ECG) and chest X ray was taken for all patients. M mode and 2D echocardiography were carried out for each patient, and the image were analyzed according to the requirement of the American society of echocardiography.

The following tests were carried out for each patient: urinalysis, complete blood picture and erythrocytes sedimentation rate, LE cell preparation, antinuclear antibody (ANA), antidouble stranded DNA, rheumatoid factor, combs test, VDRL, serum protein electrophoresis, blood urea and serum creatinine. All tests were performed using the standard methods. Statistical analysis done, using Chi-square test. A P value of < 0.05 was considered to be significant.

Results

The clinical characteristics of SLE patients are summarized in Table 1. Females were predominating (87%) with mean age of 24.9+11.4. Malar rash was the commonest manifestation (60.8%).

Table 1. Basic characteristics of the study participants (N 46).

Clinical features		Number (%)
Age (years) mean \pm SD		24.9+11.4
Sex	Male	6(13%)
	Female	40(87%)
Duration (months)		38.2 months(2-144 m)
Malar rash		28(60.8)
Discoid		11(24)
Photosensitivity		27(58.7)
Oral ulcer		24(52)
Arthritis		42(91)
Serositis		16(34.8)
Renal disorder		30(65)
Hematologic disorder		26(56.5)
Immunologic disorder		44(95)
ANA positive		41(89)
VDRL positive		12(26)

The abnormal physical findings on physical examination are shown in

table 2; unexplained sinus tachycardia was the most common finding 22%,

while cardiac murmurs were found in 19% and 69.7 % have no physical

signs. Cardiomegally was seen on Chest X ray in 20%.

Table 2. Physical signs in the patients

Sign	Number (%)
Tachycardia	10(21.7)
Cardiac murmur	9(19.5)
Irregular pulse	6(13)
S 3 and or S4	6(13)
Elevated JVP	5(11)
Displaced apex	5(11)
Pericardial rub	2(4.3)
No abnormal cardiac signs	32(69.7)

Electrocardiographic findings were summarized in (table 3). Normal ECG was seen in 65.2%, and the other findings were non specific changes. Echocardiographic study was abnormal in 31 patients (67%) (Table 4). The commonest abnormality was decrease in shortening fraction in 43%, pericardial effusion and or thickening in 32%. Mitral valve was found to be abnormal 22% (10 patients), either in form of incompetence or stenosis and or thickening, while aortic valve

incompetence was found in three patients (6.5%) only. We found that reduction in shortening fraction which is an important criterion for left ventricular function was significantly associated with symptoms suggestive of heart failure, reflecting myocardial involvement (P value < 0.05).

We did not find statistically relation between the cardiac involvement in SLE patients and the duration of the illnesses (table 5).

Table 3. Electrocardiographic finding.

Abnormality	Number (%)
ST, T changes	10(22)
Abnormal rhythm	9(19)
Ectopic beats	3(6.5)
Conduction defect	2(4.4)
LV hypertrophy	1(2.2)
Low voltage ECG	3(6.5)
Normal ECG	30(65.2)

Table 4. Echocardiographic finding in 46 patients with SLE.

Finding	Number (%)
Normal echocardiography	15(32.6)
Abnormal echocardiographic finding	
Decrease shortening fraction	20(43)
Pericardial effusion and or thickening	15(32.6)
Mitral valve involvement	10(22)
LA enlargement	10(22)
Increase LV dimension	6(13)
Increase LV wall thickness	6(13)
Aortic valve involvement	3(6.5)

Table 5. Correlation between duration of disease in months with the cardiac involvement.

Duration	Number of patient with cardiac involvement	Number of patients without cardiac involvement	Total
<12 months	6	3	9
12 -35 months	11	3	14
>36	16	7	23
Total	33	13	46

P> 0.05

Discussion

This study confirms the frequent involvement of the heart in SLE. There was a clinical evidence of cardiac abnormality in 72% of our patient, an incidence higher than that of 58% reported by Hejtmancik et al who used ECG examination and chest X ray.⁽⁷⁾ This can be explained by the fact that we used echo study which can detect asymptomatic cases of pericardial effusion and myocardial dysfunction.

The manifestations of the disease, the cumulative incidence of clinical features are similar to the current description of the disease in other series.⁽⁸⁻¹¹⁾ The cardiovascular symptoms was reported in 21 patients (46%) while abnormal cardiac finding was detected in 14 patients (30%).

There are no certain ECG changes specific for SLE. The most common abnormality detected was ST,T changes which was found in 21% of the patients, either in form ST elevation due to pericarditis or T inversion with or without ST depression due to myocarditis or coronary artery disease. Clinical evidence of coronary artery disease was found in two patients who had typical ischemic chest pain and required nitrate therapy. Patients with SLE have endothelial dysfunction that remain significant even after adjustment of other risk factors of coronary artery disease⁽¹²⁾. Low HDL cholesterol and diabetes mellitus have

a significant influence on myocardial perfusion, found in asymptomatic patients with SLE which was manifested as abnormal myocardial scintigraphy 13. Myocardial perfusion defect in SLE patients are strongly and independently predictive of coronary artery disease⁽¹⁴⁾

Low voltage ECG was found in three patients, all had significant pericardial effusion by echocardiography.

Echocardiographic examination detected abnormal finding in 31 patients (67%), the commonest was reduction in shortening fraction, which was found in 20 patients (47%), and seven of them were asymptomatic. There is significant association between symptoms suggestive of heart failure and reduction in shortening fraction measured by Echo. SLE can alter left ventricular structure and function in the absence of valvular and clinical coronary artery disease⁽¹⁵⁾. Pericardial involvement in the form of effusion and or thickening was detected in 33% an incidence which is comparable to that of 37% reported by Leung et al, who studied 75 patients with SLE by echocardiography⁹, and higher than of 25% reported by Doherty et al.⁽²⁾ Echocardiographic studies show pericardial abnormalities in between 11% and 54% of SLE patients in recent studies.⁽¹⁶⁾

Endocardial involvement in the form of valvular dysfunction, thickening, or vegetation was found in 10 patients (22%), seven of them had pure mitral valve disease, and three

patients had both mitral and aortic valve lesions. These figures are comparable to that of 24% and 5% for mitral and aortic valve involvement respectively reported by Doherty et al.⁽²⁾ Mitral valve involvement in form of incompetence was found in six patients, four of them mitral valve thickening. Mitral valve stenosis was reported in two patients and mitral thickening with out functional abnormality in two patients.

Anatomical and functional valvular abnormalities were observed in 40–50% of cases with the transthoracic echocardiography (TTE) and in 50–60% with transesophageal echocardiography (TEE).⁽¹⁷⁾ Therefore, TEE is more sensitive than TTE in revealing valve abnormalities.

Libman Sacks endocarditis was detected in one patient only (2%), a finding which is characteristic of the disease, and it was found in 43% of SLE patients at autopsy.⁽²⁾ This incidence is much lower than that 12% reported by Leung et al.⁽⁹⁾, and 9.3 reported by Galve et al.⁽¹⁸⁾ This might be explained at least partially by the relatively low resolution of our echo machine. The mitral valve thickening which was detected in six patients may be due to small vegetation which can not be differentiated by echo machine.

Aortic valve was affected in three patients, all were in form of aortic regurgitation. No one of our patients found to have tricuspid or pulmonary valve involvement. In contrast to Doherty⁽²⁾ study who reported 5% and 3% for tricuspid and pulmonary valve respectively.

The pathogenesis of the valve lesions in SLE is generally assumed to be due to the formation of fibrin platelet thrombi on the valve with subsequent organization. The deposition of thrombotic material on damaged valve

might lead to valvular thickening, commissural fusion, and ultimately to stenosis or regurgitation.⁽²⁾

In this study we did not find significant association between the duration of the disease and heart involvement, a finding which is consistent with other series, who conclude that clinically significant SLE valvular heart disease, is not necessarily the result of long standing disease.⁽⁵⁾

Study limitations

Numbers of relevant studies in patients with SLE have evidenced an association of antiphospholipid antibodies with cardiopathy, particularly in the case of Libman-Sacks endocarditis, valvar dysfunction, and valvar thickening and this was not studied in this study.⁽¹⁹⁾

Conclusion

The heart is a common target for systemic lupus erythematosus, hence special attention should be offered for examination and follow up of the cardiovascular system, including echocardiography which can detect abnormalities and can be repeated non-invasively.

References

- 1- Petri M. Systemic lupus erythematosus: clinical aspects. In Koopman WJ ed. Arthritis and allied conditions, 14th edition, volume 2, 2001, Lippincott, Williams and Wilkins, Philadelphia: 1455–1479.
- 2- Doherty NE, Siegel RJ. Cardiovascular Manifestations of systemic lupus erythematosus, American Heart Journal 1985, 110:1257-1265.
- 3- Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD, Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J. of Med. 1989, 86; 706-12.

- 4- Straaton K.V. , Chatham WW, Koopman WJ, Smith SH ,Clinical significant valvular heart disease in systemic lupus erythematosus . Am .J. of Med.1988; 85:645 -650.)
- 5- Galve E, Condell Riera J. ,Pigrau C.et al. Prevalence Morphologic types and evolution of cardiac valvular disease in systemic lupus erythematosus.N. Eng.j. Med. 1989; 319:817-822.)
- 6- Tan EM ,Cohen AS ,Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus .Arthritis Rheum 1982 ;25:1271-7.
- 7- Hejtmancik MR, Wright JC ,Q unit R, Jenning FL .The Cardiovascular manifestation of SLE . Am. Heart J.1964:68:119-130.
- 8- Dubosis EL,Tuffanell :DL. Clinical manifestation of SLE; computer analysis of 520 cases. JAMA.1964 ;190 104-111.
- 9- Leung WH ,Wong K.L. et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus . Am. J. of Medicine, Oct, 1990, 98 :411-419.
- 10- Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74: 275 ± 284.
- 11- D’Cruz D, Khamashta M, Huges GRV. Cardiovascular manifestation of systemic lupus erythematosus. In Wallace DJ and Hahn BH, eds. Dubthematosusois’ lupus erythematosus, Philadelphia: Lippincott Williams & Wilkins, 2001: 645.
- 12- Masoud El magadmi MB ;Helena Badill,Msc; et al ,Systemic lupus erythematosus an independent risk for endothelial dysfunction in women. Circulation 2004;110:399- 404.
- 13- SMC sella et al .Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Annalsof the Rhumatic diseases; 2003;62:1066-1070.
- 14- Nikpour et al .Myocardial perfusion imaging in assessing risk for coronary events in patients with systemic lupus erythematosus. The journal of rheumatology 2009 ;36 :288-294
- 15- Sebastain J Buss,Celine Johanssen et al. Echocardiographic evaluation of systolic function in ischemia and cardiomyopathy. Circulation 2008;118: s 992.
- 16- Doria A, Petri M. Cardiac involvement in systemic lupus erythematosus. In Doria A, Pauletto P, eds. The heart in systemic autoimmune disease. Amsterdam: Elsevier, Amsterdam, 2004: 146–162.
- 17- Omdal R, Lunde P, Rasmussen K et al. Transesophageal and trans thoracic echocardiography and Doppler-examination in systemic lupus erythema-tosus. Scand J Rheumatol 2001; 30: 275–281.
- 18- Galve E, Condell Riera J. ,Pigrau C.et al. Prevalence Morphologic types and evolution of cardiac valvular disease in systemic lupus erythematosus .N. Eng.j.Med. 1989; 319:817-822 .
- 19- Khamashta MA, Cervera R, Asherson RA, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus.Lancet 1990; 335: 1541-4.